MRI is Better Than SPECT in Assessing Heart Damage in Patients with Hypertrophic Cardiomyopathy
Posted on: Monday, 8 August 2005, 17:31 CDT
Contrast-enhanced MRI is better than SPECT in detecting heart damage in patients with hypertrophic cardiomyopathy, a disease that can lead to sudden death in young patients.
SPECT nuclear medicine studies are currently the most common way to look for myocardial damage in these patients; however; a new study, published in the August issue of the American Journal of Roentgenology, found that MRI is a more comprehensive examination than SPECT. “MRI was better able to detect small areas of heart damage and was able to provide us with important data on cardiac function,” said Yasuo Amano, MD, associate professor of radiology at the Nippon Medical School in Tokyo, Japan. Dr. Amano is the lead author of the study. “MRI was able to properly reflect the myocardial damages that could lead to cardiac dysfunction in patients with hypertrophic cardiomyopathy,” he said.
The study included 23 patients; 368 segments of their hearts were investigated. The patients were diagnosed with hypertrophic cardiomyopathy following an echocardiography screening examination. All of the patients had a SPECT and an MRI examination. “The results of our study indicate that contrast-enhanced MRI should be used on patients diagnosed with hypertrophic cardiomyopathy to determine the level of damage to the heart. SPECT can be done if no abnormalities appear on the MRI examination,” Dr. Amano said.
Hypertrophic cardiomyopathy is characterized by abnormal thickening of the heart wall. The disease “results from several genetic abnormalities and environmental factors,” said Dr. Amano. Its prevalence is not precisely known, although some reports indicate that it occurs in about 0.2% of the population, affecting men and women equally, he said.
On the World Wide Web:
Related Articles
- Oxygen-Saturated Blood Reduces Levels Of Damaged Heart Tissue Following Heart Attack
- Study Examines Coping Strategies Of African-American Students in Predominantly White Schools
- Heart Hospital of Austin First Site in World to Test Efficacy of New Adult Stem Cell Therapy to Treat Damaged Heart Tissue in Phase II Trial
- New Study Examines Moms by Race
- Elan and Transition Therapeutics Achieve Patient Enrollment Target in Phase 2 Clinical Study of ELND005 (AZD-103) in Alzheimer's Disease
- First Patient Enrolled in RAPID MI-ICE Study Employing InnerCool's Endovascular Temperature Modulation Therapy for Heart Attack
- Spectrum Pharmaceuticals Announces Successful Completion of Patient Accrual in Its EOquin(R) Pilot Study, Prior to Initiating Phase 3 Studies in the U.S.
- Cancer drug Gleevec may damage heart: study
- New Studies Examine SEROQUEL(R) in Combination With Antidepressant Therapy in Patients With Depression
- Infections of Febrile Neutropenic Patients in Malignant Hematological Diseases (Second Study Period)
User Comments (0)

RSS Feeds